Market News
Stay updated with the latest market trends, earnings, and economic indicators.
AB Group reaffirms bet on Voda Idea with ₹4,730 Cr infusion
Vodafone Idea shareholders approved a ₹4,730-crore investment from the Aditya Birla Group via preferential allotment of warrants, increasing AB Group's stake to around 13%. Chairman Kumar Mangalam Birla stated the company's focus now shifts to execution across operations, customer service, and network expansion. This capital infusion will support capital expenditure and loan repayment, reinforcing Vi's financial health.
Market Trading Guide: Akums Drugs among 4 stock recommendations for Thursday
Domestic equities ended lower amid global uncertainty and caution ahead of key US inflation data. Despite market weakness, analysts remain bullish on Akums Drugs and Aditya Birla Sun Life AMC after strong technical breakouts, rising volumes and improving momentum indicators.
PE investor BC Investments sells Rs 612 crore stake in Emcure Pharma; Kotak MF picks up stake
Private equity firm BC Investments IV sold a Rs 612 crore stake in Emcure Pharmaceuticals to Kotak Mahindra Mutual Fund at Rs 1,700 per share. Despite this divestment, analysts remain positive on Emcure's growth outlook across its core therapeutic segments.
Sebi may widen 50% overlap rule to thematic passive mutual fund schemes
Curb on number of smart-beta schemes also likely; move aimed at curbing proliferation in segment
Ajanta Pharma promoter sells ₹1,024 crore stake; mutual funds step in as buyers
A promoter entity of Ajanta Pharma has sold a 2.8% stake in the drugmaker for over ₹1,000 crore through a block deal, with Kotak Mahindra Mutual Fund and Aditya Birla Sun Life Mutual Fund emerging as the key buyers.
Promoter sells Rs 1,024 crore worth of Ajanta Pharma shares in block deal to Kotak MF and ABSL MF
A promoter entity of Ajanta Pharma sold shares worth over Rs 1,024 crore through a block deal, with Kotak Mahindra Mutual Fund and Aditya Birla Sun Life Mutual Fund acquiring the stake. The transaction comes amid strong earnings growth, healthy margins and sustained momentum in the company’s pharmaceutical business.
SBI in $1 billion funding for Sun Pharma’s US deal
State Bank of India is set to commit up to $1 billion to fund Sun Pharmaceutical Industries Ltd.'s $12 billion acquisition of Organon & Co. This move marks a significant step for government-run banks in financing corporate takeovers. SBI will join other global lenders in this substantial deal. The funding underscores the growing ambition of Indian companies to expand globally.
Sun Pharma, Alkem Labs, other pharma stocks gain despite stock market crash; Nifty Pharma rises for fourth day in a row - Mint
Sun Pharma, Alkem Labs, other pharma stocks gain despite stock market crash; Nifty Pharma rises for fourth day in a rowMint
7 most valued firms' mcap eroded ₹1.25 trn last week, RIL took biggest hit
The combined market valuation of seven of the top-10 most-valued firms eroded by Rs 1.25 lakh crore last week, with Reliance Industries taking the biggest hit, in-line with a bearish trend in equities. Last week, the BSE benchmark Sensex declined 532.4 points, or 0.71 per cent, and the NSE Nifty dipped 181.05 points, or 0.76 per cent. "Persistent FII selling remained the key drag on market sentiment despite supportive developments such as cooling crude oil prices and a recovery in the rupee against the US dollar. Concerns regarding the pace of monsoon advancement also weighed on investor confidence," Santosh Meena, Head of Research at Swastika Investmart Ltd, said. From the top-10 pack, Reliance Industries, Bharti Airtel, Tata Consultancy Services (TCS), Bajaj Finance, Larsen & Toubro, Life Insurance Corporation of India (LIC) and Hindustan Unilever faced erosion from their valuation, while HDFC Bank, ICICI Bank, and State Bank of India were the gainers. The market valuation of ...
Sun Pharmaceutical Industries Ltd drops for fifth straight session
Sun Pharmaceutical Industries Ltd is quoting at Rs 1774.1, down 0.81% on the day as on 13:19 IST on the NSE. The stock jumped 5.41% in last one year as compared to a 5.65% slide in NIFTY and a 11.71% spurt in the Nifty Pharma index.
Sensex falls 70 points, Nifty below 23,900 as US-Iran tensions simmer
Indian stock markets opened lower on Wednesday. Sensex and Nifty saw minor declines. Investors are watching US strikes on Iran and their effect on peace deal hopes. Broader markets are performing better. India VIX, a volatility measure, dropped. Top Sensex losers included HDFC Bank and Infosys. Sun Pharma shares led gains. Midcap and smallcap indices saw small gains.
Sensex today | Stock Market Live: Sensex drops day's gain, Nifty near 23,700; Max Health, Sun Pharma top losers - BusinessLine
Sensex today | Stock Market Live: Sensex drops day's gain, Nifty near 23,700; Max Health, Sun Pharma top losersBusinessLine